Ralph Bloomfield

8.6k total citations · 2 hit papers
50 papers, 2.7k citations indexed

About

Ralph Bloomfield is a scholar working on Genetics, Epidemiology and Psychiatry and Mental health. According to data from OpenAlex, Ralph Bloomfield has authored 50 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Genetics, 17 papers in Epidemiology and 13 papers in Psychiatry and Mental health. Recurrent topics in Ralph Bloomfield's work include Inflammatory Bowel Disease (22 papers), Microscopic Colitis (13 papers) and Attention Deficit Hyperactivity Disorder (12 papers). Ralph Bloomfield is often cited by papers focused on Inflammatory Bowel Disease (22 papers), Microscopic Colitis (13 papers) and Attention Deficit Hyperactivity Disorder (12 papers). Ralph Bloomfield collaborates with scholars based in United Kingdom, United States and Germany. Ralph Bloomfield's co-authors include Stefan Schreiber, William J. Sandborn, Ole Østergaard Thomsen, Paul Rutgeerts, Brian G. Feagan, Ian C. Lawrance, David Mason, S Stoĭnov, Stephen B. Hanauer and Juliet McColm and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Ralph Bloomfield

50 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Certolizumab Pegol for the Treatment of Crohn's Disease

2007 863 citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease

2007 766 citations Stefan Schreiber, Ian C. Lawrance et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Ralph Bloomfield

Since Specialization

Citations

This map shows the geographic impact of Ralph Bloomfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph Bloomfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph Bloomfield more than expected).

Fields of papers citing papers by Ralph Bloomfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph Bloomfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph Bloomfield. The network helps show where Ralph Bloomfield may publish in the future.

Co-authorship network of co-authors of Ralph Bloomfield

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph Bloomfield. A scholar is included among the top collaborators of Ralph Bloomfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph Bloomfield. Ralph Bloomfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis 2021 ·Cancer ·Chee Khoon Lee, Michael Friedländer, (unknown), Jonathan A. Ledermann, Robert L. Coleman, Mansoor Raza Mirza, Ursula A. Matulonis, Eric Pujade‐Lauraine, Ralph Bloomfield, Sandra Goble, Ping Wang, Rosalind Glasspool, Clare L. Scott	19
2	Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. 2019 ·Journal of Clinical Oncology ·Cara Mathews, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro	6
3	Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial 2018 ·Annals of Oncology ·Michael Friedländer, (unknown), N. Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, (unknown), Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, (unknown), (unknown), (unknown), Ralph Bloomfield, Paul DiSilvestro	1
4	Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial 2018 ·Annals of Oncology ·Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro	7
5	Exaggeration of PFS by blinded, independent, central review (BICR) 2018 ·Annals of Oncology ·A Stone, Val Gebski, Richard Davidson, Ralph Bloomfield, Jonathan W. Bartlett, (unknown)	13
6	A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder 2015 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Timothy E. Wilens, Brigitte Robertson, Vanja Sikirica, (unknown), Joel Young, Ralph Bloomfield, A. G. Lyne, (unknown), Andrew J. Cutler	42
7	Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial 2014 ·European Neuropsychopharmacology ·Amaia Hervás, Michael Huß, Mats Johnson, Fiona McNicholas, (unknown), Sasha Sreckovic, A. G. Lyne, Ralph Bloomfield, Vanja Sikirica, Brigitte Robertson	54
8	Stress levels experienced by parents of children with and without attention-deficit/hyperactivity disorder during the back-to-school period: results of a European and Canadian survey 2014 ·International Journal of Psychiatry in Clinical Practice ·(unknown), (unknown), (unknown), Antonella Gagliano, (unknown), Ralph Bloomfield, (unknown)	3
9	Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial 2013 ·European Child & Adolescent Psychiatry ·David Coghill, Tobias Banaschewski, Michel Lecendreux, Alessandro Zuddas, Regina Dittmann, (unknown), Richard Civil, Ralph Bloomfield, Liza Squires	26
10	958 – Efficacy Of Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-deficit/hyperactivity Disorder: Effect Of Age, Sex And Baseline Disease Severity 2013 ·European Psychiatry ·Michel Lecendreux, Tobias Banaschewski, César A. Soutullo, Magnus L. Johnson, Alessandro Zuddas, Colleen Anderson, Richard Civil, Nicholas Higgins, Ralph Bloomfield, Liza Squires, David Coghill	1
11	Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial 2011 ·Clinical Gastroenterology and Hepatology ·William J. Sandborn, Stefan Schreiber, Brian G. Feagan, Paul Rutgeerts, Ziad Younes, Ralph Bloomfield, G. Coteur, Juan Pablo Guzman, Geert D’Haens	133
12	Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease 2010 ·Alimentary Pharmacology & Therapeutics ·S. B. Hanauer, Julián Panés, J F Colombel, Ralph Bloomfield, Stefan Schreiber, William J. Sandborn	38
13	Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data 2010 ·The American Journal of Gastroenterology ·Stefan Schreiber, Jean‐Frédéric Colombel, Ralph Bloomfield, Susanna Nikolaus, Jürgen Schölmerich, Julián Panés, William J. Sandborn	181
14	Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study 2010 ·Clinical Gastroenterology and Hepatology ·William J. Sandborn, Stefan Schreiber, Stephen B. Hanauer, Jean–Frédéric Colombel, Ralph Bloomfield, Gary R. Lichtenstein	49
15	Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study 2010 ·Alimentary Pharmacology & Therapeutics ·Stefan Schreiber, Ian C. Lawrance, Ole Østergaard Thomsen, S. B. Hanauer, Ralph Bloomfield, W. Sandborn	113
16	Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohnʼs disease exacerbation: 3-year results from the PRECiSE 4 study 2009 ·Inflammatory Bowel Diseases ·William J. Sandborn, Stefan Schreiber, Stephen B. Hanauer, J F Colombel, Ralph Bloomfield, Gary Lichtenstein	1
17	Certolizumab Pegol for the Treatment of Crohn's Disease breakdown → 2007 ·New England Journal of Medicine ·William J. Sandborn, Brian G. Feagan, S Stoĭnov, (unknown), Paul Rutgeerts, David Mason, Ralph Bloomfield, Stefan Schreiber	863
18	Maintenance Therapy with Certolizumab Pegol for Crohn's Disease breakdown → 2007 ·New England Journal of Medicine ·Stefan Schreiber, (unknown), Ian C. Lawrance, Ole Østergaard Thomsen, Stephen B. Hanauer, Juliet McColm, Ralph Bloomfield, William J. Sandborn	766
19	Chlorpheniramine Is No More Effective than Placebo in Relieving the Symptoms of Childhood Atopic Dermatitis with a Nocturnal Itching and Scratching Component 2002 ·Dermatology ·John S. Munday, Ralph Bloomfield, (unknown), (unknown), (unknown), (unknown), (unknown), R. Marks, (unknown), (unknown)	63
20	Effect of Doxazosin Monotherapy on Blood Pressure and Plasma Lipids in Patients with Essential Hypertension 1988 ·American Journal of Hypertension ·Luigi X. Cubeddu, James L. Pool, Ralph Bloomfield, Paul E. Klotman, (unknown), Duane G. Wombolt, Edward Nelson, Alan K. Halperin	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact